Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy Abstract #1228

Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Aim(s): Assess efficacy of a multi analyte algorithmic (MAAA) blood gene transcript test and CgA in defining PRRT efficacy.
Materials and methods: NETs (n=32), M: F 22:10, median age 67, bronchial: n=8, GEP-NET: n=22, CUP: n=2 were evaluated. 19/32 were G1/G2, 19/29 were FDG+ve and 24/32 had progressive disease (PD). Status was assessed clinically and with imaging (RECIST). Cumulative Lu-PRRT activity was 4.6-27.8 GBq, median 18.5. Transcript analysis was by qRT-PCR and ELISA for CgA (EuroDiagnostica). The MAAA NETest mathematically delineates disease activity risk: scale 0-100%; minimal <20%, low: 20-47%, high >47%.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei

To read results and conclusion, please login ...

Further abstracts you may be interested in

#316 Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia
Introduction: Despite an increasing incidence, a paucity of biological information has led to major limitations in identification of plausible therapeutic targets for small intestinal neuroendocrine tumors (SINETs)
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli
#949 An Analysis of Toxicity after Peptide Receptor Radionuclide Therapy (PRRT) in 807 Patients: Determination of the Limited Predictive Role of Clinical Factors
Introduction: PRRT with 90Y-octreotide (Y) and 177Lu-octreotate (Lu) is well-tolerated.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Lisa Bodei
Authors: Bodei L, Kidd M, Grana C, Severi S, ...
Keywords: NET, PRRT, risk, toxicity
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.
Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: Biomarker, SSA
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team